Brainstorm Cell Therapeutics Inc. (BCLI) Stock Forecast
BCLI analyst forecast
as of October 21, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $17.00 average of analyst targets
- Upside to target
- +2,107.8% from the latest close
- Next earnings
- —
- 52-week range
- $0.48 – $1.44
BCLI analyst ratings
1 analystsNumber of analysts at each rating.
BCLI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BCLI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.18 | −$0.18 | −$0.19 | +5.3% | 1 |
| Current fiscal year (2026) | −$0.91 | −$0.91 | −$0.91 | −$1.11 | +18.0% | 1 |
| Next fiscal year (2027) | −$1.02 | −$1.02 | −$1.02 | −$0.91 | −12.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BCLI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
BCLI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BCLI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | $0.00 | $0.00 | −$0.18 | −14.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.07 | −$1.07 | $0.00 | $0.00 | −$0.91 | −15.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.86 | −$0.86 | $0.00 | $0.00 | −$1.02 | +18.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BCLI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BCLI beat in 8 of 11.
What analysts expect from BCLI
1 analysts cover Brainstorm Cell Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.00, 2,107.8% above the latest close of $0.77. Analysts expect earnings of −$0.91 per share for 2026, +18.0% from a year earlier. For 2027 the average estimate is −$1.02 per share. Brainstorm Cell Therapeutics beat the EPS estimate in 8 of the last 11 quarters.
Related: BCLI income statement, BCLI key metrics, BCLI chart. See the BCLI stock overview for the latest quote and news.
BCLI forecast FAQ
What is Brainstorm Cell Therapeutics's price target?
The average analyst price target for Brainstorm Cell Therapeutics is $17.00, 2,107.8% above the latest close of $0.77.
Is Brainstorm Cell Therapeutics a buy, hold or sell?
Of 1 analysts covering Brainstorm Cell Therapeutics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Brainstorm Cell Therapeutics's EPS forecast?
Analysts forecast −$0.91 per share for 2026 (range −$0.91 to −$0.91); for 2027 the estimate is −$1.02.
Does Brainstorm Cell Therapeutics usually beat earnings estimates?
Brainstorm Cell Therapeutics reported EPS at or above the analyst estimate in 8 of the last 11 quarters.